← All trials
NCT05372380
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 9, 2022
- Primary completion
- Jun 4, 2022
- Completion date
- Dec 16, 2022
- First posted
- May 12, 2022
- Last posted
- May 18, 2022
- Enrollment
- 32
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boryung Pharmaceutical CompanyLead sponsor
- Cha Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.